The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders

Frontiers in Pharmacology

Volumn 5 MAR, Issue , 2014, Pages

  Urrutia, Pamela J ^a   Mena, Natalia P ^a   Núñez, Marco T ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Inflammation; Iron toxicity; Mitochondrial dysfunction; Neurodegeneration; Parkinson's disease

Indexed keywords

HEME; HYDROXYL RADICAL; INTERLEUKIN 6; IRON; IRON SULFUR PROTEIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; FRIEDREICH ATAXIA; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; IRON OVERLOAD; MICROGLIA; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RESPIRATORY CHAIN; REVIEW;

EID: 84897952229     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00038     Document Type: Review

References (177)

1. Abramov, A. Y., Canevari, L., and Duchen, M. R. (2004). Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim. Biophys. Acta 1742, 81-87. doi: 10.1016/j.bbamcr.2004.09.006.
2. Abramov, A. Y., and Duchen, M. R. (2005). The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360, 2309-2314. doi: 10.1098/rstb.2005.1766.
3. Aliev, G., Palacios, H. H., Lipsitt, A. E., Fischbach, K., Lamb, B. T., Obrenovich, M. E., et al. (2009). Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox. Res. 16, 293-305. doi: 10.1007/s12640-009-9066-5.
4. Andersen, H. H., Johnsen, K. B., and Moos, T. (2013). Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell. Mol. Life Sci. doi: 10.1007/s00018-013-1509-8 [Epub ahead of print].
5. Angeles, D. C., Gan, B. H., Onstead, L., Zhao, Y., Lim, K. L., Dachsel, J., et al. (2011). Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum. Mutat. 32, 1390-1397. doi: 10.1002/humu.21582.
6. Arimoto, T., and Bing, G. (2003). Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 12, 35-45. doi: 10.1016/S0969-9961(02)00017-7.
7. Asenjo, A. (1968). Cytosiderosis and iron deposits in ventrolateral nucleus of the thalamus in Parkinson's disease. Clinical and experimental study. Johns Hopkins Med. J. 122, 284-294.
8. Baeuerle, P. A., and Henkel, T. (1994). Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12, 141-179. doi: 10.1146/annurev.iy.12.040194.001041.
9. Barnham, K. J., Masters, C. L., and Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3, 205-214. doi: 10.1038/nrd1330.
10. Barthwal, M. K., Srivastava, N., and Dikshit, M. (2001). Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep. 6, 297-302. doi: 10.1179/135100001101536436.
11. Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., et al. (1991). Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285, 111-114. doi: 10.1016/0014-5793(91)80737-N.
12. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306. doi: 10.1038/81834.
13. Bindoff, L. A., Birch-Machin, M., Cartlidge, N. E., Parker, W. D. Jr., and Turnbull, D. M. (1989). Mitochondrial function in Parkinson's disease. Lancet 2, 49. doi: 10.1016/S0140-6736(89)90291-2.
14. Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., and Hirsch, E. C. (1994). Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151-154. doi: 10.1016/0304-3940(94)90684-X.
15. Bouton, C., Raveau, M., and Drapier, J. C. (1996). Modulation of iron regulatory protein functions. Further insights into the role of nitrogen-and oxygen-derived reactive species. J. Biol. Chem. 271, 2300-2306. doi: 10.1074/jbc.271.4.2300.
16. Brown, G. C., and Borutaite, V. (2004). Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 1658, 44-49. doi: 10.1016/j.bbabio.2004.03.016.
17. Bruce-Keller, A. J., Gupta, S., Parrino, T. E., Knight, A. G., Ebenezer, P. J., Weidner, A. M., et al. (2010). NOX activity is increased in mild cognitive impairment. Antioxid. Redox Signal. 12, 1371-1382. doi: 10.1089/ars.2009.2823.
18. Buettner, G. R. (1993). The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300, 535-543. doi: 10.1006/abbi.1993.1074.
19. Buettner, G. R., and Schafer, F. Q. (2000). Free radicals, oxidants, and antioxidants. Teratology 62, 234. doi: 10.1002/1096-9926(200010)62:4<234::AID-TERA10>3.0.CO;2-9.
20. Bulua, A. C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K. Y., et al. (2011). Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 208, 519-533. doi: 10.1084/jem.20102049.
21. Cassina, A., and Radi, R. (1996). Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch. Biochem. Biophys. 328, 309-316. doi: 10.1006/abbi.1996.0178.
22. Chaturvedi, R. K., and Flint Beal, M. (2013). Mitochondrial diseases of the brain. Free Radic. Biol. Med. 63, 1-29. doi: 10.1016/j.freeradbiomed.2013.03.018.
23. Chinta, S. J., Kumar, M. J., Hsu, M., Rajagopalan, S., Kaur, D., Rane, A., et al. (2007). Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 27, 13997-14006. doi: 10.1523/JNEUROSCI.3885-07.2007.
24. Choi, D. H., Cristovao, A. C., Guhathakurta, S., Lee, J., Joh, T. H., Beal, M. F., et al. (2012). NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid. Redox Signal. 16, 1033-1045. doi: 10.1089/ars.2011.3960.
25. Choi, D. Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., et al. (2009). Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 4:e5482. doi: 10.1371/journal.pone.0005482.
26. Clark, W. M. (1960). Oxidation-Reduction Potentials of Organic Systems. Baltimore: Williams & Wilkins.
27. Colton, C., and Wilcock, D. M. (2010). Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 9, 174-191. doi: 10.2174/187152710791012053.
28. Colton, C. A., Wilcock, D. M., Wink, D. A., Davis, J., Van Nostrand, W. E., and Vitek, M. P. (2008). The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J. Alzheimers Dis. 15, 571-587.
29. Danielson, S. R., Held, J. M., Oo, M., Riley, R., Gibson, B. W., and Andersen, J. K. (2011). Quantitative mapping of reversible mitochondrial Complex I cysteine oxidation in a Parkinson disease mouse model. J. Biol. Chem. 286, 7601-7608. doi: 10.1074/jbc.M110.190108.
30. Davies, M. J. (2005). The oxidative environment and protein damage. Biochim. Biophys. Acta 1703, 93-109. doi: 10.1016/j.bbapap.2004.08.007.
31. Dawson, V. L., and Dawson, T. M. (1998). Nitric oxide in neurodegeneration. Prog. Brain Res. 118, 215-229. doi: 10.1016/S0079-6123(08)63210-0.
32. Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., and Schulz, J. B. (2000). Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 2213-2216. doi: 10.1046/j.1471-4159.2000.0742213.x.
33. de la Monte, S. M., and Wands, J. R. (2006). Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 9, 167-181.
34. Delatycki, M. B., Camakaris, J., Brooks, H., Evans-Whipp, T., Thorburn, D. R., Williamson, R., et al. (1999). Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45, 673-675. doi: 10.1002/1531-8249(199905)45:5<673::AID-ANA20>3.0.CO;2-Q.
35. Dexter, D., Carter, C., Agid, F., Agid, Y., Lees, A. J., Jenner, P., et al. (1986). Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2, 639-640. doi: 10.1016/S0140-6736(86)92471-2.
36. Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., et al. (1987). Increased nigral iron content in postmortem parkinsonian brain. Lancet 2, 1219-1220. doi: 10.1016/S0140-6736(87)91361-4.
37. Djafarzadeh, S., Vuda, M., Takala, J., Ochs, M., and Jakob, S. M. (2011). Toll-like receptor-3-induced mitochondrial dysfunction in cultured human hepatocytes. Mitochondrion 11, 83-88. doi: 10.1016/j.mito.2010.07.010.
38. Drapier, J. C. (1997). Interplay between NO and [Fe-S] clusters: relevance to biological systems. Methods 11, 319-329. doi: 10.1006/meth.1996.0426.
39. Drose, S., and Brandt, U. (2012). Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 748, 145-169. doi: 10.1007/978-1-4614-3573-0_6.
40. Ehrhart, J., and Zeevalk, G. D. (2003). Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. J. Neurochem. 86, 1487-1497. doi: 10.1046/j.1471-4159.2003.01954.x.
41. Emerit, J., Edeas, M., and Bricaire, F. (2004). Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58:39-46. doi: 10.1016/j.biopha.2003.11.004.
42. Enns, G. M. (2003). The contribution of mitochondria to common disorders. Mol. Genet. Metab. 80, 11-26. doi: 10.1016/j.ymgme.2003.08.009.
43. Epsztejn, S., Kakhlon, O., Glickstein, H., Breuer, W., and Cabantchik, I. (1997). Fluorescence analysis of the labile iron pool of mammalian cells. Anal. Biochem. 248, 31-40. doi: 10.1006/abio.1997.2126.
44. Eve, D. J., Nisbet, A. P., Kingsbury, A. E., Hewson, E. L., Daniel, S. E., Lees, A. J., et al. (1998). Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res. Mol. Brain Res. 63, 62-71. doi: 10.1016/S0169-328X(98)00259-9.
45. Faucheux, B. A., Martin, M. E., Beaumont, C., Hauw, J. J., Agid, Y., and Hirsch, E. C. (2003). Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86, 1142-1148. doi: 10.1046/j.1471-4159.2003.01923.x.
46. Flint, D. H., Tuminello, J. F., and Emptage, M. H. (1993). The inactivation of Fe-S cluster containing hydro-lyases by superoxide. J. Biol. Chem. 268, 22369-22376.
47. Gao, H. M., Zhang, F., Zhou, H., Kam, W., Wilson, B., and Hong, J. S. (2011). Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ. Health Perspect. 119, 807-814. doi: 10.1289/ehp.1003013.
48. Gardner, P. R., Raineri, I., Epstein, L. B., and White, C. W. (1995). Superoxide radical and iron modulate aconitase activity in mammalian cells. J. Biol. Chem. 270, 13399-13405. doi: 10.1074/jbc.270.22.13399.
49. Gautier, C. A., Corti, O., and Brice, A. (2013). Mitochondrial dysfunctions in Parkinson's disease. Rev. Neurol. (Paris) doi: 10.1016/j.neurol.2013.06.003 [Epub ahead of print].
50. Gogvadze, V., Orrenius, S., and Zhivotovsky, B. (2009). Mitochondria as targets for chemotherapy. Apoptosis 14, 624-640. doi: 10.1007/s10495-009-0323-0.
51. Graf, E., Mahoney, J. R., Bryant, R. G., and Eaton, J. W. (1984). Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 259, 3620-3624.
52. Grubman, A., White, A. R., and Liddell, J. R. (2013). Mitochondrial metals as a potential therapeutic target in neurodegeneration. Br. J. Pharmacol. doi: 10.1111/bph.12513 [Epub ahead of print].
53. Grzybicki, D., Gebhart, G. F., and Murphy, S. (1996). Expression of nitric oxide synthase type II in the spinal cord under conditions producing thermal hyperalgesia. J. Chem. Neuroanat. 10, 221-229. doi: 10.1016/0891-0618(96)00139-1.
54. Gu, M., Cooper, J. M., Taanman, J. W., and Schapira, A. H. (1998a). Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44, 177-186. doi: 10.1002/ana.410440207.
55. Gu, M., Owen, A. D., Toffa, S. E., Cooper, J. M., Dexter, D. T., Jenner, P., et al. (1998b). Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci. 158, 24-29. doi: 10.1016/S0022-510X(98)00095-1.
56. Guo, R. B., Wang, G. F., Zhao, A. P., Gu, J., Sun, X. L., and Hu, G. (2012). Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-kappaB-mediated inflammatory responses. PLoS ONE 7:e49701. doi: 10.1371/journal.pone.0049701.
57. Haile, D. J., Rouault, T. A., Tang, C. K., Chin, J., Harford, J. B., and Klausner, R. D. (1992). Reciprocal control of RNA-binding and aconitase activity in the regulation of the iron-responsive element binding protein: role of the iron-sulfur cluster. Proc. Natl. Acad. Sci. U.S.A. 89, 7536-7540. doi: 10.1073/pnas.89.16.7536.
58. Hanke, M. L., and Kielian, T. (2011). Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin. Sci. 121, 367-387. doi: 10.1042/CS20110164.
59. Harley, A., Cooper, J. M., and Schapira, A. H. (1993). Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res. 627, 349-353. doi: 10.1016/0006-8993(93)90341-J.
60. Hausladen, A., and Fridovich, I. (1994). Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J. Biol. Chem. 269, 29405-29408.
61. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1984). Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224, 1451-1453. doi: 10.1126/science.6610213.
62. Hensley, K., Robinson, K. A., Gabbita, S. P., Salsman, S., and Floyd, R. A. (2000). Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med. 28, 1456-1462. doi: 10.1016/S0891-5849(00)00252-5.
63. Hernandes, M. S., Santos, G. D., Cafe-Mendes, C. C., Lima, L. S., Scavone, C., Munhoz, C. D., et al. (2013). Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration. PLoS ONE 8:e75532. doi: 10.1371/journal.pone.0075532.
64. Hewett, J. A., and Hewett, S. J. (2012). Induction of nitric oxide synthase-2 expression and measurement of nitric oxide production in enriched primary cortical astrocyte cultures. Methods Mol. Biol. 814, 251-263. doi: 10.1007/978-1-61779-452-0_17.
65. Hider, R. C., and Kong, X. L. (2011). Glutathione: a key component of the cytoplasmic labile iron pool. Biometals 24, 1179-1187. doi: 10.1007/s10534-011-9476-8.
66. Hirsch, E. C., and Hunot, S. (2009). Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8, 382-397. doi: 10.1016/S1474-4422(09)70062-6.
67. Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., et al. (2000). alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410. doi: 10.1016/S0002-9440(10)64553-1.
68. Huang, M. L., Becker, E. M., Whitnall, M., Suryo Rahmanto, Y., Ponka, P., and Richardson, D. R. (2009). Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl. Acad. Sci. U.S.A. 106, 16381-16386. doi: 10.1073/pnas.0906784106.
69. Huh, S. H., Chung, Y. C., Piao, Y., Jin, M. Y., Son, H. J., Yoon, N. S., et al. (2011). Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J. Immunol. 187, 960-969. doi: 10.4049/jimmunol.1100009.
70. Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M. P., Ruberg, M., et al. (1997). Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 94, 7531-7536. doi: 10.1073/pnas.94.14.7531.
71. Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H. C., et al. (2007). Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 100, 1375-1386. doi: 10.1111/j.1471-4159.2006.04327.x.
72. Hunter, R. L., Liu, M., Choi, D. Y., Cass, W. A., and Bing, G. (2008). Inflammation and age-related iron accumulation in F344 rats. Curr. Aging Sci. 1, 112-121. doi: 10.2174/1874609810801020112.
73. Jellinger, K. A. (2009). Recent advances in our understanding of neurodegeneration. J. Neural Transm. 116, 1111-1162. doi: 10.1007/s00702-009-0240-y.
74. Jha, N., Jurma, O., Lalli, G., Liu, Y., Pettus, E. H., Greenamyre, J. T., et al. (2000). Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem. 275, 26096-26101. doi: 10.1074/jbc.M000120200.
75. Jomova, K., Vondrakova, D., Lawson, M., and Valko, M. (2010). Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem. 345, 91-104. doi: 10.1007/s11010-010-0563-x.
76. Junn, E., Jang, W. H., Zhao, X., Jeong, B. S., and Mouradian, M. M. (2009). Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J. Neurosci. Res. 87, 123-129. doi: 10.1002/jnr.21831.
77. Kakhlon, O., and Cabantchik, Z. I. (2002). The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic. Biol. Med. 33, 1037-1046. doi: S0891584902010067.
78. Kawamoto, E. M., Lima, L. S., Munhoz, C. D., Yshii, L. M., Kinoshita, P. F., Amara, F. G., et al. (2012). Influence of N-methyl-D-aspartate receptors on ouabain activation of nuclear factor-kappaB in the rat hippocampus. J. Neurosci. Res. 90, 213-228. doi: 10.1002/jnr.22745.
79. Keeney, P. M., Xie, J., Capaldi, R. A., and Bennett, J. P. Jr. (2006). Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256-5264. doi: 10.1523/JNEUROSCI.0984-06.2006.
80. Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., et al. (2011). Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J. Immunol. 187, 6539-6549. doi: 10.4049/jimmunol.1100620.
81. Kiyota, T., Yamamoto, M., Xiong, H., Lambert, M. P., Klein, W. L., Gendelman, H. E., et al. (2009). CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE 4:e6197. doi: 10.1371/journal.pone.0006197.
82. Knott, C., Stern, G., and Wilkin, G. P. (2000). Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2. Mol. Cell. Neurosci. 16, 724-739. doi: 10.1006/mcne.2000.0914.
83. Kokovay, E., and Cunningham, L. A. (2005). Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis. 19, 471-478. doi: 10.1016/j.nbd.2005.01.023.
84. Kumfu, S., Chattipakorn, S., Fucharoen, S., and Chattipakorn, N. (2012). Mitochondrial calcium uniporter blocker prevents cardiac mitochondrial dysfunction induced by iron overload in thalassemic mice. Biometals 25, 1167-1175. doi: 10.1007/s10534-012-9579-x.
85. Langston, J. W., and Ballard, P. A. Jr. (1983). Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309, 310. doi: 10.1056/NEJM198308043090511.
86. Langston, J. W., Irwin, I., Langston, E. B., and Forno, L. S. (1984). Pargyline prevents MPTP-induced parkinsonism in primates. Science 225, 1480-1482. doi: 10.2307/1693552.
87. Lavigne, M. C., Malech, H. L., Holland, S. M., and Leto, T. L. (2001). Genetic requirement of p47phox for superoxide production by murine microglia. FASEB J. 15, 285-287. doi: 10.1096/fj.00-0608fje.
88. Lee, D. W., Kaur, D., Chinta, S. J., Rajagopalan, S., and Andersen, J. K. (2009). A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. Antioxid. Redox Signal. 11, 2083-2094. doi: 10.1089/ARS.2009.2489.
89. Lee, Y. W., Lee, W. H., and Kim, P. H. (2010). Oxidative mechanisms of IL-4-induced IL-6 expression in vascular endothelium. Cytokine 49, 73-79. doi: 10.1016/j.cyto.2009.08.009.
90. L'Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Serra, P. A., Impagnatiello, F., et al. (2010). Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroinflammation 7, 83. doi: 10.1186/1742-2094-7-83.
91. Liang, L. P., and Patel, M. (2004). Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. J. Neurochem. 90, 1076-1084. doi: 10.1111/j.1471-4159.2004.02567.x.
92. Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., Mcauliffe, W. G., et al. (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403-1409. doi: 10.1038/70978.
93. Lipinski, B. (2011). Hydroxyl radical and its scavengers in health and disease. Oxid. Med. Cell. Longev. 2011, 809696. doi: 10.1155/2011/809696.
94. Ludwiczek, S., Aigner, E., Theurl, I., and Weiss, G. (2003). Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101, 4148-4154. doi: 10.1182/blood-2002-08-2459.
95. Mandemakers, W., Morais, V. A., and De Strooper, B. (2007). A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 120, 1707-1716. doi: 10.1242/jcs.03443.
96. Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., et al. (2006). Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50. doi: 10.1523/JNEUROSCI.4308-05.2006.
97. McGeer, P. L., Itagaki, S., and Mcgeer, E. G. (1988). Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76, 550-557. doi: 10.1007/BF00689592.
98. Mello-Filho, A. C., and Meneghini, R. (1991). Iron is the intracellular metal involved in the production of DNA damage by oxygen radicals. Mutat. Res. 251, 109-113. doi: 10.1016/0027-5107(91)90220-I.
99. Mena, N. P., Bulteau, A. L., Salazar, J., Hirsch, E. C., and Núñez, M. T. (2011). Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity. Biochem. Biophys. Res. Commun. 409, 241-246. doi: 10.1016/j.bbrc.2011.04.137.
100. Michaeli, S., Oz, G., Sorce, D. J., Garwood, M., Ugurbil, K., Majestic, S., et al. (2007). Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov. Disord. 22, 334-340. doi: 10.1002/mds.21227.
101. Millis, K. K., Weaver, K. H., and Rabenstein, D. L. (1993). Oxidation/reduction potential of glutathione. J. Org. Chem. 58, 4144-4146. doi: 10.1021/jo00067a060.
102. Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., Sato, T., et al. (1989). Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455. doi: 10.1016/0006-291X(89)91141-8.
103. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., et al. (1994). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150. doi: 10.1016/0304-3940(94)90508-8.
104. Moreira, P. I., Zhu, X., Wang, X., Lee, H. G., Nunomura, A., Petersen, R. B., et al. (2010). Mitochondria: a therapeutic target in neurodegeneration. Biochim. Biophys. Acta 1802, 212-220. doi: 10.1016/j.bbadis.2009.10.007.
105. Muckenthaler, M. U., Galy, B., and Hentze, M. W. (2008). Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 28, 197-213. doi: 10.1146/annurev.nutr.28.061807.155521.
106. Mulero, V., and Brock, J. H. (1999). Regulation of iron metabolism in murine J774 macrophages: role of nitric oxide-dependent and-independent pathways following activation with gamma interferon and lipopolysaccharide. Blood 94, 2383-2389. doi: 10.1074/jbc.275.9.6220.
107. Muller, T., Blum-Degen, D., Przuntek, H., and Kuhn, W. (1998). Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand. 98, 142-144. doi: 10.1111/j.1600-0404.1998.tb01736.x.
108. Nagatsu, T. (2002). Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. J. Neural Transm. 109, 731-745. doi: 10.1007/s007020200061.
109. Nicklas, W. J., Vyas, I., and Heikkila, R. E. (1985). Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508. doi: 10.1016/0024-3205(85)90146-8.
110. Noh, K. M., and Koh, J. Y. (2000). Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J. Neurosci. 20, RC111.
111. Núñez, M. T., Gallardo, V., Muñoz, P., Tapia, V., Esparza, A., Salazar, J., et al. (2004). Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells. Free Radic. Biol. Med. 37, 953-960. doi: 10.1016/j.freeradbiomed.2004.06.005.
112. Núñez, M. T., Tapia, V., Toyokuni, S., and Okada, S. (2001). Iron-induced oxidative damage in colon carcinoma (Caco-2) cells. Free Radic. Res. 34, 57-68. doi: 10.1080/10715760100300061.
113. Núñez, M. T., Urrutia, P., Mena, N., Aguirre, P., Tapia, V., and Salazar, J. (2012). Iron toxicity in neurodegeneration. Biometals 25, 761-776. doi: 10.1007/s10534-012-9523-0.
114. Núñez-Millacura, C., Tapia, V., Muñoz, P., Maccioni, R. B., and Núñez, M. T. (2002). An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J. Neurochem. 82, 240-248. doi: 10.1046/j.1471-4159.2002.00971.x.
115. Nunomura, A., Perry, G., Pappolla, M. A., Wade, R., Hirai, K., Chiba, S., et al. (1999). RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964.
116. Paradkar, P. N., and Roth, J. A. (2006). Nitric oxide transcriptionally down-regulates specific isoforms of divalent metal transporter (DMT1) via NF-kappaB. J. Neurochem. 96, 1768-1777. doi: 10.1111/j.1471-4159.2006.03702.x.
117. Park, L., Zhou, P., Pitstick, R., Capone, C., Anrather, J., Norris, E. H., et al. (2008). Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 105, 1347-1352. doi: 10.1073/pnas.0711568105.
118. Pawate, S., Shen, Q., Fan, F., and Bhat, N. R. (2004). Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J. Neurosci. Res. 77, 540-551. doi: 10.1002/jnr.20180.
119. Pelizzoni, I., Macco, R., Morini, M. F., Zacchetti, D., Grohovaz, F., and Codazzi, F. (2011). Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell 10, 172-183. doi: 10.1111/j.1474-9726.2010.00652.x.
120. Perry, T. L., Godin, D. V., and Hansen, S. (1982). Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310. doi: 10.1016/0304-3940(82)90390-1.
121. Petrat, F., De Groot, H., and Rauen, U. (2001). Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells. Biochem. J. 356, 61-69. doi: 10.1042/0264-6021:3560061.
122. Petrat, F., De Groot, H., Sustmann, R., and Rauen, U. (2002). The chelatable iron pool in living cells: a methodically defined quantity. Biol. Chem. 383, 489-502. doi: 10.1515/BC.2002.051.
123. Pezzoli, G., and Cereda, E. (2013). Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 80, 2035-2041. doi: 10.1212/WNL.0b013e318294b3c8.
124. Phani, S., Loike, J. D., and Przedborski, S. (2012). Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl 1), S207-S209. doi: 10.1016/S1353-8020(11)70064-5.
125. Pierre, J. L., and Fontecave, M. (1999). Iron and activated oxygen species in biology: the basic chemistry. Biometals 12, 195-199. doi: 10.1023/A:1009252919854.
126. Possel, H., Noack, H., Putzke, J., Wolf, G., and Sies, H. (2000). Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 32, 51-59. doi: 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4.
127. Ridder, D. A., and Schwaninger, M. (2009). NF-kappaB signaling in cerebral ischemia. Neuroscience 158, 995-1006. doi: 10.1016/j.neuroscience.2008.07.007.
128. Rothwell, N. J., and Luheshi, G. N. (2000). Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 23, 618-625. doi: 10.1016/S0166-2236(00)01661-1.
129. Rouault, T. A., and Tong, W. H. (2005). Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat. Rev. Mol. Cell Biol. 6, 345-351. doi: 10.1038/nrm1620.
130. Sareila, O., Kelkka, T., Pizzolla, A., Hultqvist, M., and Holmdahl, R. (2011). NOX2 complex-derived ROS as immune regulators. Antioxid. Redox Signal. 15, 2197-2208. doi: 10.1089/ars.2010.3635.
131. Sas, K., Robotka, H., Toldi, J., and Vecsei, L. (2007). Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 257, 221-239. doi: 10.1016/j.jns.2007.01.033.
132. Schapira, A. H., and Cooper, J. M. (1992). Mitochondrial function in neurodegeneration and ageing. Mutat. Res. 275, 133-143. doi: 10.1016/0921-8734(92)90018-K.
133. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990). Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827. doi: 10.1111/j.1471-4159.1990.tb02325.x.
134. Schapira, A. H., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., and Marsden, C. D. (1989). Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269. doi: 10.1016/S0140-6736(89)92366-0.
135. Sen, C. K., and Packer, L. (1996). Antioxidant and redox regulation of gene transcription. FASEB J. 10, 709-720.
136. Seyidova, D., Aliyev, A., Rzayev, N., Obrenovich, M., Lamb, B. T., Smith, M. A., et al. (2004). The role of nitric oxide in the pathogenesis of brain lesions during the development of Alzheimer's disease. In Vivo 18, 325-333.
137. Shand, O., and Volz, K. (2013). The solution structure of apo-iron regulatory protein 1. Gene 524, 341-346. doi: 10.1016/j.gene.2013.03.112.
138. Shi, H. X., Liu, X., Wang, Q., Tang, P. P., Liu, X. Y., Shan, Y. F., et al. (2011). Mitochondrial ubiquitin ligase MARCH5 promotes TLR7 signaling by attenuating TANK action. PLoS Pathog. 7:e1002057. doi: 10.1371/journal.ppat.1002057.
139. Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., et al. (2000). Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273, 5-9. doi: 10.1006/bbrc.2000.2897.
140. Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E. M., et al. (2005). Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14, 3477-3492. doi: 10.1093/hmg/ddi377.
141. Singh, S., Das, T., Ravindran, A., Chaturvedi, R. K., Shukla, Y., Agarwal, A. K., et al. (2005). Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Redox Rep. 10, 103-109. doi: 10.1179/135100005X38842.
142. Skalnik, D. G., Strauss, E. C., and Orkin, S. H. (1991). CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. J. Biol. Chem. 266, 16736-16744.
143. Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., and Perry, G. (1997). Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-2657.
144. Sochaski, M. A., Bartfay, W. J., Thorpe, S. R., Baynes, J. W., Bartfay, E., Lehotay, D. C., et al. (2002). Lipid peroxidation and protein modification in a mouse model of chronic iron overload. Metabolism 51, 645-651. doi: 10.1053/meta.2002.30530.
145. Song, Y., Qu, R., Zhu, S., Zhang, R., and Ma, S. (2012). Rhynchophylline attenuates LPS-induced pro-inflammatory responses through down-regulation of MAPK/NF-kappaB signaling pathways in primary microglia. Phytother. Res. 26, 1528-1533. doi: 10.1002/ptr.4614.
146. Su, K., Bourdette, D., and Forte, M. (2013). Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front. Physiol. 4:169. doi: 10.3389/fphys.2013.00169.
147. Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Binder, D. R., Bennett, J. P. Jr., Di Iorio, G., et al. (2001). Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp. Neurol. 169, 479-485. doi: 10.1006/exnr.2001.7674.
148. Swerdlow, R. H., Parks, J. K., Miller, S. W., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., et al. (1996). Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40, 663-671. doi: 10.1002/ana.410400417.
149. Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., et al. (2011). Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119, 866-872. doi: 10.1289/ehp.1002839.
150. Tatsumi, T., Matoba, S., Kawahara, A., Keira, N., Shiraishi, J., Akashi, K., et al. (2000). Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J. Am. Coll. Cardiol. 35, 1338-1346. doi: 10.1016/S0735-1097(00)00526-X.
151. Teeuwsen, V. J., Schalken, J. J., Van Der Groen, G., Van De Akker, R., Goudsmit, J., and Osterhaus, A. D. (1991). An inhibition enzyme immunoassay using a human monoclonal antibody (K14) reactive with gp41 of HIV-1 for the serology of HIV-1 infections. AIDS 5, 893-896. doi: 10.1097/00002030-199107000-00017.
152. Thannickal, V. J., and Fanburg, B. L. (2000). Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L1005-L1028.
153. Tieu, K., Ischiropoulos, H., and Przedborski, S. (2003). Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55, 329-335. doi: 10.1080/1521654032000114320.
154. Tobon-Velasco, J. C., Limon-Pacheco, J. H., Orozco-Ibarra, M., Macias-Silva, M., Vazquez-Victorio, G., Cuevas, E., et al. (2013). 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-kappaB factors. Toxicology 304, 109-119. doi: 10.1016/j.tox.2012.12.011.
155. Ueda, S., Masutani, H., Nakamura, H., Tanaka, T., Ueno, M., and Yodoi, J. (2002). Redox control of cell death. Antioxid. Redox Signal. 4, 405-414. doi: 10.1089/15230860260196209.
156. Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N. P., Arredondo, M., et al. (2013). Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 126, 541-549. doi: 10.1111/jnc.12244.
157. Vodovotz, Y., Lucia, M. S., Flanders, K. C., Chesler, L., Xie, Q. W., Smith, T. W., et al. (1996). Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184, 1425-1433. doi: 10.1084/jem.184.4.1425.
158. Wallace, M. N., Geddes, J. G., Farquhar, D. A., and Masson, M. R. (1997). Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp. Neurol. 144, 266-272. doi: 10.1006/exnr.1996.6373.
159. Wang, J., Song, N., Jiang, H., and Xie, J. (2013). Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons. Biochim. Biophys. Acta 1832, 618-625. doi: 10.1016/j.bbadis.2013.01.021.
160. Wang, X., Garrick, M. D., Yang, F., Dailey, L. A., Piantadosi, C. A., and Ghio, A. J. (2005). TNF, IFN-gamma, and endotoxin increase expression of DMT1 in bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L24-L33. doi: 10.1152/ajplung.00428.2003.
161. Wardrop, S. L., and Richardson, D. R. (2000). Interferon-gamma and lipopolysaccharide regulate the expression of Nramp2 and increase the uptake of iron from low relative molecular mass complexes by macrophages. Eur. J. Biochem. 267, 6586-6593. doi: 10.1046/j.1432-1327.2000.01752.x.
162. West, A. P., Brodsky, I. E., Rahner, C., Woo, D. K., Erdjument-Bromage, H., Tempst, P., et al. (2011). TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472, 476-480. doi: 10.1038/nature09973.
163. Wood, P. M. (1988). The potential diagram for oxygen at pH 7. Biochem. J. 253, 287-289.
164. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., et al. (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.
165. Wu, D. C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., et al. (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 6145-6150. doi: 10.1073/pnas.0937239100.
166. Xie, Z., Smith, C. J., and Van Eldik, L. J. (2004). Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia 45, 170-179. doi: 10.1002/glia.10314.
167. Yang, C. S., Kim, J. J., Lee, S. J., Hwang, J. H., Lee, C. H., Lee, M. S., et al. (2013). TLR3-triggered reactive oxygen species contribute to inflammatory responses by activating signal transducer and activator of transcription-1. J. Immunol. 190, 6368-6377. doi: 10.4049/jimmunol.1202574.
168. Yang, C. S., Shin, D. M., Kim, K. H., Lee, Z. W., Lee, C. H., Park, S. G., et al. (2009). NADPH oxidase 2 interaction with TLR2 is required for efficient innate immune responses to mycobacteria via cathelicidin expression. J. Immunol. 182, 3696-3705. doi: 10.4049/jimmunol.0802217.
169. Yang, F., Liu, X. B., Quinones, M., Melby, P. C., Ghio, A., and Haile, D. J. (2002). Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J. Biol. Chem. 277, 39786-39791. doi: 10.1074/jbc.M201485200.
170. Yokoyama, H., Takagi, S., Watanabe, Y., Kato, H., and Araki, T. (2008). Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J. Neural Transm. 115, 831-842. doi: 10.1007/s00702-008-0019-6.
171. Zecca, L., Wilms, H., Geick, S., Claasen, J. H., Brandenburg, L. O., Holzknecht, C., et al. (2008). Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 116, 47-55. doi: 10.1007/s00401-008-0361-7.
172. Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R., and Crichton, R. R. (2004). Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873. doi: 10.1038/nrn1537.
173. Zhang, F., Zhou, H., Wilson, B. C., Shi, J. S., Hong, J. S., and Gao, H. M. (2012). Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat. Disord. 18(Suppl 1), S213-S217. doi: 10.1016/S1353-8020(11)70066-9.
174. Zhang, J., Stanton, D. M., Nguyen, X. V., Liu, M., Zhang, Z., Gash, D., et al. (2005). Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience 135, 829-838. doi: 10.1016/j.neuroscience.2005.06.049.
175. Zhang, W., Wang, T., Qin, L., Gao, H. M., Wilson, B., Ali, S. F., et al. (2004). Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 18, 589-591. doi: 10.1096/fj.03-0983fje.
176. Zhang, X., and Lemasters, J. J. (2013). Translocation of iron from lysosomes to mitochondria during ischemia predisposes to injury after reperfusion in rat hepatocytes. Free Radic. Biol. Med. 63, 243-253. doi: 10.1016/j.freeradbiomed.2013.05.004.
177. Zoccarato, F., Toscano, P., and Alexandre, A. (2005). Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J. Biol. Chem. 280, 15587-15594. doi: 10.1074/jbc.M500657200.